Who is sponsoring NCT00100126?

NCT00100126 is sponsored by Advancis Pharmaceutical Corporation.

What drugs are being tested in NCT00100126?

Interventions in NCT00100126: Amoxicillin Pulsatile Release Multiparticluate Sprinkle.

What condition does NCT00100126 study?

NCT00100126 studies Pharyngitis.

Is NCT00100126 still recruiting?

NCT00100126 is currently completed. Last updated 23 October 2006.

Last reviewed 2006-10-23 · How we verify

NCT00100126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III, Investigator Blind, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of APC-231 Sprinkle QD for 7 Days vs Penicillin VK 10 mg/kg QID for 10 Days in Pediatric Patients With Streptococcus Pyogenes

Completed Phase 3 Last updated 23 October 2006

What this trial tests

Phase 3 trial testing Amoxicillin Pulsatile Release Multiparticluate Sprinkle in Pharyngitis in 500 participants. Completed in 1 June 2005.

Timeline

1 December 2004

1 June 2005

Quick facts

Lead sponsor	Advancis Pharmaceutical Corporation
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	500
Start date	1 December 2004
Estimated completion	1 June 2005
Sites	2 locations across United States

Drugs / interventions tested

Amoxicillin Pulsatile Release Multiparticluate Sprinkle — full drug profile →

Conditions studied

Pharyngitis — all drugs for Pharyngitis →

Sponsor

Advancis Pharmaceutical Corporation — full company profile →

Who can join

Adults 6 Months to 12, any sex, with Pharyngitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Bacteriological outcome at Test of Cure Visit

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of APC-231 QD for 7 days in the bacteriological outcome at the Test of Cure Visit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pharyngitis

Currently open trials in the same condition.

NCT06859281 — Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers · Phase 1 · recruiting
NCT06857890 — Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy · Phase 1 · recruiting
NCT06843018 — Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray · Phase 2 · recruiting
NCT06114706 — Best Assessment of Sore Throat and Antibiotic Prescribing · NA · recruiting
NCT04471493 — Pediatric and Ambulatory Research in Infectious Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00100126 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Advancis Pharmaceutical Corporation
Last refreshed: 23 October 2006

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00100126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing